Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Uterine Fibroid Treatment Drugs Market
Uterine Fibroid Treatment Drugs Market Share
- Report ID: GMI6506
- Published Date: Aug 2023
- Report Format: PDF
Uterine Fibroid Treatment Drugs Market Share
The key players in the uterine fibroid treatment drugs market are
- Pfizer Inc.
- Abbvie, Inc.
- AstraZeneca plc
- Bayer AG
- Myovant Sciences Gmbh
- Ferring B.V.
- Amring Pharmaceuticals Inc.
- Theramex and Watson Pharma, Inc.
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Frequently Asked Questions (FAQ) :
Uterine fibroid treatment drugs industry size reached USD 1.7 billion in 2022 and will witness 10% CAGR through 2032 due to the emergence of novel medications for individuals with uterine fibroids.
Progestin-releasing intrauterine device (IUD) & contraceptives segment registered 65.7% share in 2022 on account of its advantages in managing the uterine fibroids.
North America uterine fibroid treatment drugs industry will witness 9.4% CAGR through 2023-2032 owing to the increasing demand for non-invasive, safe, and effective treatment options in the region.
Pfizer Inc., Abbvie, Inc., AstraZeneca plc, Bayer AG, Myovant Sciences Gmbh, Ferring B.V., Amring Pharmaceuticals Inc., Theramex and Watson Pharma, Inc. are some of the major uterine fibroid treatment drug companies worldwide.
Uterine Fibroid Treatment Drugs Market Scope
×
Get a free sample of
Uterine Fibroid Treatment Drugs Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below